Please enable JavaScript to continue using this application.

Compare $MDGL vs $PCVX | Chartloom

Compare

$MDGL vs $PCVX

Madrigal Pharmaceuticals Inc · Vaxcyte Inc

MDGL

Madrigal Pharmaceuticals Inc

PCVX

Vaxcyte Inc

Compare $MDGL vs $PCVX

Comparing Madrigal Pharmaceuticals Inc and Vaxcyte Inc

MDGLMadrigal Pharmaceuticals Inc

PCVXVaxcyte Inc

MDGLMadrigal Pharmaceuticals Inc

Market cap

$10.88B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.94x

Rev growth (TTM)

149.0%

YTD performance

-20.6%

52W performance

8.0%

FCF yield

-1.9%

PCVXVaxcyte Inc

Market cap

$10.31B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

53.6%

52W performance

75.2%

FCF yield

-8.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MDGL

PCVX

Detailed metrics comparison

MDGL

Madrigal Pharmaceuticals Inc

PCVX

Vaxcyte Inc

Market Cap

MDGL$10.88B

PCVX$10.31B

Enterprise Value

MDGL$10.93B

PCVX$10.12B

Price

MDGL$471.75

PCVX$71.38

P/E Ratio

MDGLN/A

PCVXN/A

P/S Ratio

MDGL8.47x

PCVX0.00x

EV/Sales

MDGL8.51x

PCVX0.00x

EV/EBITDA

MDGL699.23x

PCVX0.00x

P/B Ratio

MDGL22.03x

PCVX3.05x

P/FCF Ratio

MDGLN/A

PCVXN/A

EV/FCF

MDGL-52.02x

PCVX-10.99x

PEG Ratio

MDGLN/A

PCVXN/A

Forward P/E (NTM)

MDGLN/A

PCVXN/A

Forward P/S (NTM)

MDGL5.94x

PCVXN/A

Revenue (TTM)

MDGL$1.28B

PCVX$0

Revenue Growth (YoY)

MDGL149.0%

PCVXN/A

Forward Rev Growth

MDGL41.6%

PCVX157.2%

Gross Margin (TTM)

MDGL91.5%

PCVX0.0%

Operating Margin (TTM)

MDGL0.0%

PCVX0.0%

EBITDA Margin (TTM)

MDGL-25.0%

PCVX0.0%

Net Margin (TTM)

MDGL-25.3%

PCVX0.0%

FCF Margin (TTM)

MDGL-16.4%

PCVXN/A

Net Income (TTM)

MDGL$-325M

PCVX$-1.06B

FCF (TTM)

MDGL$-210M

PCVX$-921M

EPS (TTM)

MDGL-$11.15

PCVX-$7.37

ROE (TTM)

MDGL-5665.0%

PCVX-3757.0%

ROA (TTM)

MDGL-2553.0%

PCVX-3362.0%

ROIC (TTM)

MDGL-3556.0%

PCVX-3757.0%

Cash

MDGL$293M

PCVX$183M

Debt

MDGL$341M

PCVX$0

Net Cash/Debt

MDGL$-48M

PCVX$183M

Current Ratio (TTM)

MDGL3.20x

PCVX5.72x

Quick Ratio (TTM)

MDGL2.76x

PCVX5.48x

Debt/Equity (TTM)

MDGL0.65x

PCVX0.00x

Debt/Assets (TTM)

MDGL0.0%

PCVX0.0%

Interest Coverage (TTM)

MDGLN/A

PCVXN/A

Net Debt/EBITDA (TTM)

MDGL0.00x

PCVX0.00x

Beta

MDGL-1.08

PCVX1.31

52W Performance

MDGL8.0%

PCVX75.2%

YTD Performance

MDGL-20.6%

PCVX53.6%

% from 52W High

MDGL-23.3%

PCVX-21.3%

% from 52W Low

MDGL19.9%

PCVX79.0%

Asset Turnover (TTM)

MDGL1.01x

PCVX0.00x

FCF Yield (TTM)

MDGL-1.9%

PCVX-8.9%

Earnings Yield (TTM)

MDGL-3.0%

PCVX-10.3%

Dividend Yield (TTM)

MDGLN/A

PCVXN/A

Rule of 40

MDGL132.7

PCVX0.0

EV/GP/RG

MDGL0.21

PCVXN/A

Ticker research

View MDGL research View PCVX research

Metric	MDGL Madrigal Pharmaceuticals Inc	PCVX Vaxcyte Inc
Market & Valuation
Market Cap	$10.88B	$10.31B
Enterprise Value	$10.93B	$10.12B
Price	$471.75	$71.38
P/E Ratio	N/A	N/A
P/S Ratio	8.47x	0.00x
EV/Sales	8.51x	0.00x
EV/EBITDA	699.23x	0.00x
P/B Ratio	22.03x	3.05x
P/FCF Ratio	N/A	N/A
EV/FCF	-52.02x	-10.99x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	5.94x	N/A
Revenue & Growth
Revenue (TTM)	$1.28B	$0
Revenue Growth (YoY)	149.0%	N/A
Forward Rev Growth	41.6%	157.2%
Profitability
Gross Margin (TTM)	91.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-25.0%	0.0%
Net Margin (TTM)	-25.3%	0.0%
FCF Margin (TTM)	-16.4%	N/A
Net Income (TTM)	$-325M	$-1.06B
FCF (TTM)	$-210M	$-921M
EPS (TTM)	-$11.15	-$7.37
ROE (TTM)	-5665.0%	-3757.0%
ROA (TTM)	-2553.0%	-3362.0%
ROIC (TTM)	-3556.0%	-3757.0%
Financial Health
Cash	$293M	$183M
Debt	$341M	$0
Net Cash/Debt	$-48M	$183M
Current Ratio (TTM)	3.20x	5.72x
Quick Ratio (TTM)	2.76x	5.48x
Debt/Equity (TTM)	0.65x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.08	1.31
52W Performance	8.0%	75.2%
YTD Performance	-20.6%	53.6%
% from 52W High	-23.3%	-21.3%
% from 52W Low	19.9%	79.0%
Efficiency & Yields
Asset Turnover (TTM)	1.01x	0.00x
FCF Yield (TTM)	-1.9%	-8.9%
Earnings Yield (TTM)	-3.0%	-10.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	132.7	0.0
EV/GP/RG	0.21	N/A
Ticker research	View MDGL research	View PCVX research

Valuation

P/S Ratio

PCVX

0.00x

MDGL

8.47x

EV/FCF

MDGL

-52.02x

PCVX

-10.99x

Growth & revenue

Revenue Growth TTM

MDGL

149.0%

Forward Revenue Growth

PCVX

157.2%

MDGL

41.6%

Profitability & performance

Gross Margin

MDGL

91.5%

PCVX

0.0%

ROE

PCVX

-3757.0%

MDGL

-5665.0%

FCF Yield %

MDGL

-1.9%

PCVX

-8.9%

52-Week Performance

PCVX

75.2%

MDGL

8.0%

Detailed metrics comparison

MDGL

Madrigal Pharmaceuticals Inc

PCVX

Vaxcyte Inc

Market Cap

MDGL$10.88B

PCVX$10.31B

Enterprise Value

MDGL$10.93B

PCVX$10.12B

Price

MDGL$471.75

PCVX$71.38

P/E Ratio

MDGLN/A

PCVXN/A

P/S Ratio

MDGL8.47x

PCVX0.00x

EV/Sales

MDGL8.51x

PCVX0.00x

EV/EBITDA

MDGL699.23x

PCVX0.00x

P/B Ratio

MDGL22.03x

PCVX3.05x

P/FCF Ratio

MDGLN/A

PCVXN/A

EV/FCF

MDGL-52.02x

PCVX-10.99x

PEG Ratio

MDGLN/A

PCVXN/A

Forward P/E (NTM)

MDGLN/A

PCVXN/A

Forward P/S (NTM)

MDGL5.94x

PCVXN/A

Revenue (TTM)

MDGL$1.28B

PCVX$0

Revenue Growth (YoY)

MDGL149.0%

PCVXN/A

Forward Rev Growth

MDGL41.6%

PCVX157.2%

Gross Margin (TTM)

MDGL91.5%

PCVX0.0%

Operating Margin (TTM)

MDGL0.0%

PCVX0.0%

EBITDA Margin (TTM)

MDGL-25.0%

PCVX0.0%

Net Margin (TTM)

MDGL-25.3%

PCVX0.0%

FCF Margin (TTM)

MDGL-16.4%

PCVXN/A

Net Income (TTM)

MDGL$-325M

PCVX$-1.06B

FCF (TTM)

MDGL$-210M

PCVX$-921M

EPS (TTM)

MDGL-$11.15

PCVX-$7.37

ROE (TTM)

MDGL-5665.0%

PCVX-3757.0%

ROA (TTM)

MDGL-2553.0%

PCVX-3362.0%

ROIC (TTM)

MDGL-3556.0%

PCVX-3757.0%

Cash

MDGL$293M

PCVX$183M

Debt

MDGL$341M

PCVX$0

Net Cash/Debt

MDGL$-48M

PCVX$183M

Current Ratio (TTM)

MDGL3.20x

PCVX5.72x

Quick Ratio (TTM)

MDGL2.76x

PCVX5.48x

Debt/Equity (TTM)

MDGL0.65x

PCVX0.00x

Debt/Assets (TTM)

MDGL0.0%

PCVX0.0%

Interest Coverage (TTM)

MDGLN/A

PCVXN/A

Net Debt/EBITDA (TTM)

MDGL0.00x

PCVX0.00x

Beta

MDGL-1.08

PCVX1.31

52W Performance

MDGL8.0%

PCVX75.2%

YTD Performance

MDGL-20.6%

PCVX53.6%

% from 52W High

MDGL-23.3%

PCVX-21.3%

% from 52W Low

MDGL19.9%

PCVX79.0%

Asset Turnover (TTM)

MDGL1.01x

PCVX0.00x

FCF Yield (TTM)

MDGL-1.9%

PCVX-8.9%

Earnings Yield (TTM)

MDGL-3.0%

PCVX-10.3%

Dividend Yield (TTM)

MDGLN/A

PCVXN/A

Rule of 40

MDGL132.7

PCVX0.0

EV/GP/RG

MDGL0.21

PCVXN/A

Ticker research

View MDGL research View PCVX research

Metric	MDGL Madrigal Pharmaceuticals Inc	PCVX Vaxcyte Inc
Market & Valuation
Market Cap	$10.88B	$10.31B
Enterprise Value	$10.93B	$10.12B
Price	$471.75	$71.38
P/E Ratio	N/A	N/A
P/S Ratio	8.47x	0.00x
EV/Sales	8.51x	0.00x
EV/EBITDA	699.23x	0.00x
P/B Ratio	22.03x	3.05x
P/FCF Ratio	N/A	N/A
EV/FCF	-52.02x	-10.99x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	5.94x	N/A
Revenue & Growth
Revenue (TTM)	$1.28B	$0
Revenue Growth (YoY)	149.0%	N/A
Forward Rev Growth	41.6%	157.2%
Profitability
Gross Margin (TTM)	91.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-25.0%	0.0%
Net Margin (TTM)	-25.3%	0.0%
FCF Margin (TTM)	-16.4%	N/A
Net Income (TTM)	$-325M	$-1.06B
FCF (TTM)	$-210M	$-921M
EPS (TTM)	-$11.15	-$7.37
ROE (TTM)	-5665.0%	-3757.0%
ROA (TTM)	-2553.0%	-3362.0%
ROIC (TTM)	-3556.0%	-3757.0%
Financial Health
Cash	$293M	$183M
Debt	$341M	$0
Net Cash/Debt	$-48M	$183M
Current Ratio (TTM)	3.20x	5.72x
Quick Ratio (TTM)	2.76x	5.48x
Debt/Equity (TTM)	0.65x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.08	1.31
52W Performance	8.0%	75.2%
YTD Performance	-20.6%	53.6%
% from 52W High	-23.3%	-21.3%
% from 52W Low	19.9%	79.0%
Efficiency & Yields
Asset Turnover (TTM)	1.01x	0.00x
FCF Yield (TTM)	-1.9%	-8.9%
Earnings Yield (TTM)	-3.0%	-10.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	132.7	0.0
EV/GP/RG	0.21	N/A
Ticker research	View MDGL research	View PCVX research